Mammalian stable expression of biotherapeutics.
Many therapeutically relevant proteins, like IgG antibodies, are highly complex, multimeric glycoproteins that are difficult to express in microbial systems and thus usually produced in mammalian host cells. During the past two decades, stable mammalian expression technologies have made huge progress resulting in highly increased speed of cell line development and yield of manufacturing processes. Here, we give an overview of technologies that are applied at different stages of state-of-the-art cell line development processes for biomanufacturing.
Novartis Pharma AG, Basel, Switzerland. Thomas.jostock@novartis.com
Thomas
T
Jostock
Hans-Peter
HP
Knopf
D000818:Animals; D000906:Antibodies / Q000235:genetics / Q000302:isolation & purification; D016466:CHO Cells / Q000166:cytology; D006224:Cricetinae; D005821:Genetic Techniques; D005822:Genetic Vectors; D057166:High-Throughput Screening Assays; D006801:Humans; D007074:Immunoglobulin G / Q000096:biosynthesis / Q000235:genetics / Q000302:isolation & purification; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000235:genetics / Q000302:isolation & purification; D014162:Transfection / Q000379:methods
D000906:Antibodies; D007074:Immunoglobulin G; D011994:Recombinant Proteins